Anti-Napsin-A Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody raised against the catalytic domain of human Napsin-A, validated for Western blot.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential
UniProt
O96009
Size
100ug
Cat. #
RP3NapsinB

In stock

SKU
RP-NapsinB

Options

As low as: $130.00

Target Overview

Napsin-A (NAPSA, UniProt O96009) is a secreted aspartyl protease belonging to the pepsin family of proteolytic enzymes (EC 3.4.23.-). Also designated as aspartyl protease 4 (ASP4) or Napsin-1, this 420-amino acid enzyme is highly expressed in type II pneumocytes of the lung and in proximal renal tubules. Napsin-A is thought to participate in processing surfactant protein precursors in alveolar epithelium, though its precise physiological substrates remain incompletely defined. The protein has gained significant research attention as a biomarker: Napsin-A is expressed in approximately 80% of lung adenocarcinomas and is frequently used alongside TTF-1 in diagnostic immunohistochemistry panels to distinguish pulmonary from extrapulmonary adenocarcinomas. Its restricted tissue distribution and robust expression in lung adenocarcinoma make it a valuable marker in surgical pathology and a candidate tumor-associated antigen in immunotherapy studies.

Background

Napsin-A functions as an aspartic endopeptidase optimally active at acidic pH. The protein is synthesized as a preproenzyme and undergoes proteolytic maturation to generate the active form. While its role in surfactant metabolism has been proposed based on expression patterns in alveolar epithelium, knockout studies and substrate identification remain areas of ongoing investigation. Napsin-A exhibits structural homology to cathepsin D and other pepsin-like aspartyl proteases, with a characteristic bilobal architecture and active-site aspartate residues essential for catalysis. In diagnostic pathology, Napsin-A has become a cornerstone marker for lung adenocarcinoma, particularly in distinguishing primary pulmonary tumors from metastatic disease. The marker demonstrates high specificity when combined with TTF-1, though occasional aberrant expression has been documented in non-pulmonary contexts, including gastric adenocarcinomas arising in the setting of autoimmune metaplastic atrophic gastritis. Recent work by Toussieng et al (2026) highlights this phenomenon, emphasizing the importance of clinical context when interpreting immunohistochemical profiles. Emerging research has identified Napsin-A as a potential immunotherapy target. Miller et al (2025) reported that Napsin-A-specific T-cell clonotypes correlate with improved clinical outcomes in patients with metastatic non-small cell lung cancer treated with checkpoint inhibitors, suggesting that endogenous immune responses to this tumor-associated antigen may contribute to therapeutic efficacy. This observation has renewed interest in Napsin-A not only as a diagnostic tool but as a candidate neoantigen for vaccine development and adoptive cell therapies.

References

  1. Miller NJ et al (2025) Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer. J Immunother Cancer. PubMed · DOI
  2. Toussieng T et al (2026) Pulmonary immunohistochemical markers may be positive in gastric adenocarcinomas associated with autoimmune metaplastic atrophic gastritis. Histopathology. PubMed · DOI
  3. Nacer DF et al (2026) Multiomics assessment of lung adenocarcinoma subtypes defined through tumor purity-adjusted DNA methylation. Genome Med. PubMed · DOI

Additional Specifications

Gene Symbol NAPSA
UniProt ID O96009
Host Species Rabbit
Species Reactivity Validated- Human
Potential
Pack Size 100ug
Immunogen (Catalytic domain Napsin-B (512 amino acid form))Immunogen is proprietary and confidential. Immunogen generated in amino acid region 78-399.
Immunogen (Carboxyterminal end Napsin-B)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 370-420.
Alternate Names NAPSA, Napsin-A, Napsin-1, Aspartyl protease 4, ASP4, Asp 4, TA01/TA02, EC 3.4.23.-

Frequently Asked Questions

What molecular weight band should I expect for Napsin-A on Western blot?

Napsin-A migrates at approximately 42–45 kDa on reduced SDS-PAGE, corresponding to the mature processed form. The full-length precursor (pre-pro-enzyme) is 420 amino acids with a predicted mass near 46 kDa, but the signal peptide and activation peptide are cleaved during maturation and secretion. You may occasionally observe higher molecular weight species around 50–55 kDa representing glycosylated or incompletely processed forms, particularly in cell lysates versus conditioned media. The mature secreted protease is the predominant form in lung tissue and most adenocarcinoma samples.

What starting dilution should I use for Western blot with this Napsin antibody?

We recommend starting at 1:1000 dilution for Western blot applications with this rabbit polyclonal antibody, as validated in our hands. This dilution typically provides robust signal from lung adenocarcinoma cell lysates or tissue homogenates when loading 20–30 µg total protein per lane. If your samples express Napsin-A at lower levels or you observe high background, you may need to optimize between 1:500 and 1:2000. Always include a positive control lysate from A549 or H1299 lung adenocarcinoma cells to confirm antibody performance before troubleshooting sample-specific issues.

Does this Napsin antibody distinguish between Napsin-A and Napsin-B isoforms?

This antibody is specific for Napsin-A (gene name NAPSA, UniProt O96009) and does not cross-react with Napsin-B (encoded by the NAPSB gene). Napsin-B shares only limited sequence homology with Napsin-A and exhibits different tissue distribution, primarily in kidney and testis rather than lung. The immunogen used to generate this polyclonal antibody corresponds to regions unique to the Napsin-A protein sequence. If your research requires detection of Napsin-B, you will need a separate antibody designed against that specific isoform.

Will this rabbit polyclonal Napsin antibody work for immunohistochemistry on FFPE lung tissue?

Yes, This antibody is validated for Western blot; immunohistochemistry/immunofluorescence validation is in progress applications on formalin-fixed paraffin-embedded tissue. Napsin-A shows characteristic cytoplasmic granular staining in type II pneumocytes of normal lung and diffuse cytoplasmic positivity in approximately 80% of pulmonary adenocarcinomas. Antigen retrieval is typically required; heat-mediated retrieval in citrate buffer pH 6.0 is a reliable starting point. Optimal dilution for IHC may differ from Western blot and should be titrated on your specific tissue sections, but 1:100 to 1:500 is a reasonable starting range.

Is this Napsin-A antibody validated in species other than human?

This antibody is validated specifically for human Napsin-A. Cross-reactivity with mouse or rat Napsin-A is not confirmed and should be considered predicted rather than demonstrated. Human and mouse Napsin-A share approximately 75–80% amino acid identity, so cross-reactivity is plausible, but you should verify signal specificity using knockout tissue or cells if working with rodent samples. If your experimental model requires robust detection in mouse lung, we recommend validating this antibody in parallel with a known positive control and considering a species-specific antibody if signal is weak or equivocal.

What positive and negative control samples should I use when validating this Napsin antibody?

For Western blot, A549 or H1299 lung adenocarcinoma cell lysates serve as strong positive controls, as both cell lines express endogenous Napsin-A. Normal adult lung tissue homogenate also works well. HeLa or HEK293 cells are useful negative controls since they lack detectable Napsin-A expression. For IHC, normal lung parenchyma (type II pneumocytes positive) and lung adenocarcinoma tissue are ideal positives, while squamous cell carcinoma or small cell lung cancer typically show minimal to absent staining. Renal proximal tubules also express Napsin-A and can serve as an additional positive tissue control.

How should I store this Napsin antibody and how long will it remain stable?

Store the antibody at –20°C in small aliquots to avoid repeated freeze-thaw cycles, which can reduce antibody activity over time. The 100 µg vial is provided as a liquid or lyophilized preparation; verify format on your product datasheet. If liquid, supplement with carrier protein such as 0.1% BSA or 50% glycerol to enhance stability during storage. Properly stored aliquots typically remain stable for at least 12 months at –20°C. Avoid prolonged storage at 4°C for working aliquots; prepare only what you need for one week of experiments.

Why do I see multiple bands on my Napsin-A Western blot?

Multiple bands likely reflect differential glycosylation or proteolytic processing of Napsin-A. The mature enzyme migrates at 42–45 kDa, but you may detect a minor band at 50–55 kDa representing the glycosylated precursor or pro-form. Lower molecular weight fragments below 40 kDa can arise from autocatalytic cleavage, especially in lysates stored without protease inhibitors, since Napsin-A is an active aspartyl protease. Additionally, some lung adenocarcinoma cells produce alternatively processed forms. Include fresh protease inhibitors during lysis and compare your pattern to a validated positive control to distinguish biological complexity from degradation artifacts.

Western blot validation for RP-NapsinB — 2 panels across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

Napsin: Catalytic domain Napsin-B (512 amino acid form) — WB validation
WB · Panel 1 Napsin: Catalytic domain Napsin-B (512 amino acid form)
Napsin: Carboxyterminal end Napsin-B — WB validation
WB · Panel 2 Napsin: Carboxyterminal end Napsin-B

Custom validation studies available on request — contact us.

Also known as:

  • NAPSA
  • Napsin-A
  • Napsin-1
  • Aspartyl protease 4
  • ASP4
  • Asp 4
  • TA01/TA02
  • EC 3.4.23.-
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →